Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.W | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Question for Eoganacht

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon May 12, 2023 6:44pm

117 Views

Post# 35446468

RE:RE:RE:RE:RE:RE:Question for Eoganacht

DJDawg wrote:
51% of enrollees end up being responders.

Achieving is CR is just the start. Then you have to hold that response.

Ruvidar is achieving 60% of enrollees becoming CR which is better.

Then the quote mentions that "Forty-six percent of responding patients remained in complete response for at least one year". So 46% of 51% is the percent of enrollees that are CR at one year plus.

Maybe we are getting confused by definitions
Enrollees sign up and start on the med
Responders achieve a CR at a point that is usually within a number of months of enrolling
A percent of responders keep being CR

A responder is not always a sustained responded. The may fall off with return of the cancer.